| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Daniel J Drucker, Jens J Hols. The expanding incretin universe: from basic biology to clinical translation. Diabetologia. 2023-03-28. PMID:36976349. |
incretin hormones, principally glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1(glp-1), potentiate meal-stimulated insulin secretion through direct (gip + glp-1) and indirect (glp-1) actions on islet β-cells. |
2023-03-28 |
2023-08-14 |
Not clear |
| Nathalie Esser, Thomas O Mundinger, Breanne M Barrow, Sakeneh Zraik. Acute Inhibition of Intestinal Neprilysin Enhances Insulin Secretion Via GLP-1 Receptor Signaling in Male Mice. Endocrinology. 2023-03-25. PMID:36964914. |
acute inhibition of intestinal neprilysin enhances insulin secretion via glp-1 receptor signaling in male mice. |
2023-03-25 |
2023-08-14 |
mouse |
| Shannon L Castek, Lindsey C Healey, Deanna S Kania, Veronica P Vernon, Andrea J Dawso. Assessment of Glucagon-like Peptide-1 Receptor Agonists in Veterans Taking Basal/Bolus Insulin Regimens. Federal practitioner : for the health care professionals of the VA, DoD, and PHS. vol 39. issue Suppl 5. 2023-03-16. PMID:36923548. |
clinical use of glucagon-like peptide-1 receptor agonists (glp-1 ras) is well established as add-on therapy to oral medications and basal insulin. |
2023-03-16 |
2023-08-14 |
Not clear |
| Shannon L Castek, Lindsey C Healey, Deanna S Kania, Veronica P Vernon, Andrea J Dawso. Assessment of Glucagon-like Peptide-1 Receptor Agonists in Veterans Taking Basal/Bolus Insulin Regimens. Federal practitioner : for the health care professionals of the VA, DoD, and PHS. vol 39. issue Suppl 5. 2023-03-16. PMID:36923548. |
however, there is little published data regarding the use of glp-1 ras for longer than 12 months in patients taking basal/bolus insulin regimens. |
2023-03-16 |
2023-08-14 |
Not clear |
| Shannon L Castek, Lindsey C Healey, Deanna S Kania, Veronica P Vernon, Andrea J Dawso. Assessment of Glucagon-like Peptide-1 Receptor Agonists in Veterans Taking Basal/Bolus Insulin Regimens. Federal practitioner : for the health care professionals of the VA, DoD, and PHS. vol 39. issue Suppl 5. 2023-03-16. PMID:36923548. |
the primary goal of our study was to assess the long-term efficacy of glp-1 ras as add-on therapy to basal/bolus insulin regimens. |
2023-03-16 |
2023-08-14 |
Not clear |
| Jhih-Syuan Liu, Sheng-Chiang Su, Feng-Chih Kuo, Peng-Fei Li, Chia-Luen Huang, Li-Ju Ho, Kuan-Chan Chen, Yi-Chen Liu, Chih-Ping Lin, An-Che Cheng, Chien-Hsing Lee, Fu-Huang Lin, Yi-Jen Hung, Hsin-Ya Liu, Chieh-Hua Lu, Chang-Hsun Hsie. The efficacy and safety of combined GLP-1RA and basal insulin therapy among inadequately controlled T2D with premixed insulin therapy. Medicine. vol 102. issue 10. 2023-03-10. PMID:36897731. |
this study investigated the effect of a combination of glucagon-like peptide-1 receptor agonist (glp-1 ra) and basal insulin (bi) in poorly controlled type 2 diabetes mellitus previously treated with premixed insulin. |
2023-03-10 |
2023-08-14 |
human |
| Jhih-Syuan Liu, Sheng-Chiang Su, Feng-Chih Kuo, Peng-Fei Li, Chia-Luen Huang, Li-Ju Ho, Kuan-Chan Chen, Yi-Chen Liu, Chih-Ping Lin, An-Che Cheng, Chien-Hsing Lee, Fu-Huang Lin, Yi-Jen Hung, Hsin-Ya Liu, Chieh-Hua Lu, Chang-Hsun Hsie. The efficacy and safety of combined GLP-1RA and basal insulin therapy among inadequately controlled T2D with premixed insulin therapy. Medicine. vol 102. issue 10. 2023-03-10. PMID:36897731. |
the antidiabetic regimen was switched to glp-1 ra plus bi to replace previous treatment with premixed insulin in type 2 diabetes mellitus subjects. |
2023-03-10 |
2023-08-14 |
human |
| Jhih-Syuan Liu, Sheng-Chiang Su, Feng-Chih Kuo, Peng-Fei Li, Chia-Luen Huang, Li-Ju Ho, Kuan-Chan Chen, Yi-Chen Liu, Chih-Ping Lin, An-Che Cheng, Chien-Hsing Lee, Fu-Huang Lin, Yi-Jen Hung, Hsin-Ya Liu, Chieh-Hua Lu, Chang-Hsun Hsie. The efficacy and safety of combined GLP-1RA and basal insulin therapy among inadequately controlled T2D with premixed insulin therapy. Medicine. vol 102. issue 10. 2023-03-10. PMID:36897731. |
the initial insulin dose of premixed insulin was 61 ± 18 units, and the final insulin dose of glp-1 ra + bi was 32 ± 12 units (p < .001). |
2023-03-10 |
2023-08-14 |
human |
| Zhongnan Xu, Zhengzhi Liu, Yanli Wang, Jinling Xue, Tianying Chang, Yingzi Cui, Yang Cheng, Guangwen Liu, Wanhua Wang, Yannan Zhou, Shuang Yu, Qing Ren, Wei Yang, Xinyao Qu, Jiahui Chen, Xuesong Chen, Qiaohuan Deng, Haimiao Yang, Xiuge Wan. Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trial. Expert review of clinical pharmacology. 2023-03-08. PMID:36883362. |
liraglutide, a glp-1 receptor agonist, can lower blood sugar by increasing insulin production and inhibiting the production of glucagon. |
2023-03-08 |
2023-08-14 |
human |
| Antonella M D'Ascanio, Jamie A Mullally, William H Frishma. Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. Cardiology in review. 2023-03-08. PMID:36883831. |
semaglutide, a glp-1 receptor agonist, reduces appetite via glp-1 receptors in the hypothalamus and increases the production of insulin, and reduces glucagon secretion, delaying gastric emptying. |
2023-03-08 |
2023-08-14 |
Not clear |
| Priyanshu Nema, Vivek Asati, Priyadarshi Kendya, Twinkle Gupta, Shivangi Agarwal, Shivam Kori, Varsha Kashaw, Arun K Iyer, Sushil Kumar Kasha. Structural Insight on GPR119 Agonist as Potential Therapy for Type II Diabetes: A Comprehensive Review. Mini reviews in medicinal chemistry. 2023-03-02. PMID:36861804. |
gpr119 has been linked to the control of insulin release by pancreatic β-cells, as well as the generation of glp-1 by enteroendocrine cells in the gut, as per in vitro assays. |
2023-03-02 |
2023-08-14 |
Not clear |
| Michael M Richter, Maria S Svane, Viggo B Kristiansen, Jens J Holst, Sten Madsbad, Kirstine N Bojsen-Mølle. Postprandial secretion of follistatin after gastric bypass surgery and sleeve gastrectomy. Peptides. 2023-02-26. PMID:36842630. |
we investigated circulating follistatin after mixed-meals in two cohorts of patients who were part of previously published studies and had undergone bariatric surgery with either simultaneous assessment of amino acid absorption or administration of the glp-1 receptor antagonist exendin-(9-39), which increased glucagon concentrations and impaired insulin secretion. |
2023-02-26 |
2023-08-14 |
human |
| Tomohiro Komatsu, Satomi Abe, Shihoko Nakashima, Kei Sasaki, Yasuki Higaki, Keijiro Saku, Shin-Ichiro Miura, Yoshinari Uehar. Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Phosphate Accelerates Cellular Cholesterol Efflux in THP-1 Cells. Biomolecules. vol 13. issue 2. 2023-02-25. PMID:36830597. |
glp-1 plays an important role in regulating insulin secretion and expression via the glp-1 receptor (glp-1r), which is expressed in pancreatic islets as well as freshly isolated human monocytes and thp-1 cells. |
2023-02-25 |
2023-08-14 |
human |
| Bo Ahré. Contribution of GIP and GLP-1 to the Insulin Response to Oral Administration of Glucose in Female Mice. Biomedicines. vol 11. issue 2. 2023-02-25. PMID:36831127. |
contribution of gip and glp-1 to the insulin response to oral administration of glucose in female mice. |
2023-02-25 |
2023-08-14 |
mouse |
| Bo Ahré. Contribution of GIP and GLP-1 to the Insulin Response to Oral Administration of Glucose in Female Mice. Biomedicines. vol 11. issue 2. 2023-02-25. PMID:36831127. |
now, i have proceeded and studied the contribution of glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1) to the insulin response to oral glucose in female mice by using receptor antagonists. |
2023-02-25 |
2023-08-14 |
mouse |
| Jarosław Nuszkiewicz, Jolanta Czuczejko, Wiktor Dróżdż, Alina Woźniak, Bogdan Małkowski, Karolina Szewczyk-Gole. Concentration of Selected Adipokines and Factors Regulating Carbohydrate Metabolism in Patients with Head and Neck Cancer in Respect to Their Body Mass Index. International journal of molecular sciences. vol 24. issue 4. 2023-02-25. PMID:36834693. |
the aim of the study was to determine the concentrations of ghrelin, omentin-1, adipsin, adiponectin, leptin, resistin, visfatin, glucagon, insulin, c-peptide, glucagon-like peptide-1 (glp-1), plasminogen activator inhibitor-1 (pai-1), and gastric inhibitory peptide (gip) in the blood serum of hnc patients depending on their body mass index (bmi). |
2023-02-25 |
2023-08-14 |
Not clear |
| Hideaki Miyoshi, Munehide Matsuhisa, Daisuke Yabe, Yoko Takahashi, Yukiko Morimoto, Yasuo Terauch. Use of iGlarLixi for the Management of Type 2 Diabetes in Japanese Clinical Practice: Prior Treatment Subgroup Analysis of the SPARTA Japan Study. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2023-02-22. PMID:36809494. |
iglarlixi, a fixed-ratio combination of insulin glargine 100 u/ml and the glucagon-like peptide 1 receptor agonist (glp-1 ra) lixisenatide, is one option for treatment intensification in individuals with type 2 diabetes (t2d) who are unable to achieve targeted glycaemic control with their current glucose-lowering agent. |
2023-02-22 |
2023-08-14 |
Not clear |
| Erik Elebring, Anna Casselbrant, Sara M T Persson, Lars Fändriks, Ville Walleniu. βHB inhibits glucose-induced GLP-1 secretion in GLUTag and human jejunal enteroids. Journal of molecular endocrinology. 2023-02-22. PMID:36810364. |
glucagon-like peptide-1 (glp-1) is one of these incretins that stimulates postprandial insulin release and signals satiety to the brain. |
2023-02-22 |
2023-08-14 |
human |
| Xiu-Ping Bai, Wen-Jin Du, Hua-Bing Xing, Guo-Hua Yang, Rui Ba. Influence of ursodeoxycholic acid on blood glucose, insulin and GLP-1 in rats with liver fibrosis induced by bile duct ligation. Diabetology & metabolic syndrome. vol 15. issue 1. 2023-02-15. PMID:36788623. |
influence of ursodeoxycholic acid on blood glucose, insulin and glp-1 in rats with liver fibrosis induced by bile duct ligation. |
2023-02-15 |
2023-08-14 |
rat |
| Ece Guler, Ayse Nur Hazar-Yavuz, Esra Tatar, Mohammad Morid Haidari, Gul Sinemcan Ozcan, Gokhan Duruksu, Manuel Pedro F Graça, Deepak M Kalaskar, Oguzhan Gunduz, Muhammet Emin Ca. Oral empagliflozin-loaded tri-layer core-sheath fibers fabricated using tri- axial electrospinning: Enhanced in vitro and in vivo antidiabetic performance. International journal of pharmaceutics. 2023-02-15. PMID:36791999. |
the levels of glp-1, ppar-γ, and insulin were increased while the levels of sglt-2 and tnf-α were decreased with emf treatment. |
2023-02-15 |
2023-08-14 |
rat |